
June 5 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:
NRX PHARMACEUTICALS, INC. (NASDAQ:NRXP) FILES ABBREVIATED NEW DRUG APPLICATION (ANDA) FOR PRESERVATIVE-FREE IV KETAMINE
NRX PHARMACEUTICALS INC - ANTICIPATES PRIORITY REVIEW DUE TO KETAMINE SHORTAGE
NRX PHARMACEUTICALS INC - NDA SUBMISSION FOR NRX-100 IN SUICIDAL DEPRESSION, PDUFA EXPECTED LATE 2025